» Articles » PMID: 21641589

Temperaments Mediate Suicide Risk and Psychopathology Among Patients with Bipolar Disorders

Overview
Specialty Psychiatry
Date 2011 Jun 7
PMID 21641589
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several studies have demonstrated that bipolar II (BD-II) disorder represents a quite common, distinct form of major mood disorders that should be separated from bipolar I (BD-I) disorder. The aims of this cross-sectional study were to assess temperament and clinical differences between patients with BD-I and BD-II disorders and to assess whether temperament traits are good predictors of hopelessness in patients with bipolar disorder, a variable highly associated with suicidal behavior and ideation.

Method: Participants were 216 consecutive inpatients (97 men and 119 women) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), BD who were admitted to the Sant'Andrea Hospital's psychiatric ward in Rome (Italy). Patients completed the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego--Autoquestionnaire, the Beck Hopelessness Scale (BHS), the Mini International Neuropsychiatric Interview (MINI), and the Gotland Scale of Male Depression.

Results: Patients with BD-II had higher scores on the BHS (9.78 ± 5.37 vs 6.87 ± 4.69; t(143.59) = -3.94; P < .001) than patients with BD-I. Hopelessness was associated with the individual pattern of temperament traits (ie, the relative balance of hyperthymic vs cyclothymic-irritable-anxious-dysthmic). Furthermore, patients with higher hopelessness (compared with those with lower levels of hopelessness) reported more frequently moderate to severe depression (87.1% vs 38.9%; P < .001) and higher MINI suicidal risk.

Conclusion: Temperaments are important predictors both of suicide risk and psychopathology and may be used in clinical practice for better delivery of appropriate care to patients with bipolar disorders.

Citing Articles

Relevant factors contributing to risk of suicide among adolescents.

Cheng L, Song W, Zhao Y, Zhang H, Wang J, Lin J BMC Psychiatry. 2025; 25(1):217.

PMID: 40069653 PMC: 11895159. DOI: 10.1186/s12888-024-06421-8.


Serum L-selectin levels as predictive markers for chronic major depressive disorder progression.

Yun Y, Mun S, Lee S, Kang H, Lee J Ann Gen Psychiatry. 2024; 23(1):37.

PMID: 39415236 PMC: 11481545. DOI: 10.1186/s12991-024-00522-0.


Unidentified genotype does not affect pharmacological treatment for patients with first episode psychosis.

De Brabander E, van Amelsvoort T, van Westrhenen R J Psychopharmacol. 2024; 38(12):1111-1121.

PMID: 39344086 PMC: 11528939. DOI: 10.1177/02698811241279022.


Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.

Kwasny A, Cubala W, Wlodarczyk A, Pastuszak K Pharmacol Rep. 2024; 76(6):1325-1332.

PMID: 39207673 PMC: 11582297. DOI: 10.1007/s43440-024-00641-1.


Global, regional, and national time trends in incidence for depressive disorders, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019.

Wu Y, Fan L, Xia F, Zhou Y, Wang H, Feng L Ann Gen Psychiatry. 2024; 23(1):28.

PMID: 39095916 PMC: 11297615. DOI: 10.1186/s12991-024-00513-1.